Coronary revascularization in patients with HIV

McCutcheon, Keir; Triantafyllis, Andreas S.; Eynde, Jef Van den; Oosterlinck, Wouter; Vachiat, Ahmed; Tsabedze, Nqoba; Zachariah, Don; Manga, Pravin; Bennett, Johan

doi:10.1016/j.tcm.2021.02.006

Cited by 5 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[90][91][92] Coronary revascularization in PLWH is more complicated than in the general population because of coagulopathy, persistent inflammation, drug-to-drug interactions, and insufficient data guiding decision-making. 93 Data regarding major adverse cardiovascular events after revascularization are conflicting. Death from ASCVD has increased among PLWH, and long-term outcomes remain worse for PLWH after a cardiovascular event.…”

Section: Atherosclerotic Cvdmentioning

confidence: 99%

Cardiac and Renal Comorbidities in Aging People Living With HIV

McCutcheon,

Nqebelele,

Murray

et al. 2024

Circulation Research

Self Cite

View full text Add to dashboard Cite

Contemporary World Health Organization data indicates that ≈39 million people are living with the human immunodeficiency virus. Of these, 24 million have been reported to have successfully accessed combination antiretroviral therapy. In 1996, the World Health Organization endorsed the widespread use of combination antiretroviral therapy, transforming human immunodeficiency virus infection from being a life-threatening disease to a chronic illness characterized by multiple comorbidities. The increased access to combination antiretroviral therapy has translated to people living with human immunodeficiency virus (PLWH) no longer having a reduced life expectancy. Although aging as a biological process increases exposure to oxidative stress and subsequent systemic inflammation, this effect is likely enhanced in PLWH as they age. This narrative review engages the intricate interplay between human immunodeficiency virus associated chronic inflammation, combination antiretroviral therapy, and cardiac and renal comorbidities development in aging PLWH. We examine the evolving demographic profile of PLWH, emphasizing the increasing prevalence of aging individuals within this population. A central focus of the review discusses the pathophysiological mechanisms that underpin the heightened susceptibility of PLWH to renal and cardiac diseases as they age.

show abstract

Section: Atherosclerotic Cvdmentioning

confidence: 99%

Cardiac and Renal Comorbidities in Aging People Living With HIV

McCutcheon,

Nqebelele,

Murray

et al. 2024

Circulation Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…For instance, we encountered a similar issue when studying the literature about coronary artery disease in patients with HIV. 4 These patients often experience recurrent major adverse cardiovascular events following revascularization. Nonetheless, various studies failed to show any difference with regard to major adverse cardiovascular event–free survival between HIV-positive versus HIV-negative patients.…”

mentioning

confidence: 99%